IL6 and cancer: Certain signaling pathways were increased in cancer patient PBMCs (IL-10-induced p-STAT3 in helper T, Treg, and cytotoxic T cells) while others were decreased (IL-6 induced p-STAT1 in helper T, Treg, and cytotoxic T cells) compared to healthy control PBMCs.